Crohn's Disease Diagnostic and Therapeutic Market
|発行||Mordor Intelligence LLP||商品コード||391371|
|出版日||ページ情報||英文 113 Pages
|クローン病診断および治療の世界市場：成長、動向と予測 Crohn's Disease Diagnostic and Therapeutic Market|
|出版日: 2019年05月01日||ページ情報: 英文 113 Pages||
The global Crohn's disease diagnostic and therapeutics market is estimated to grow at a CAGR of 3.1% during the forecast period. Crohn's disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals.
Increasing awareness of the Crohn's disease, coupled with rising initiatives by regulatory bodies for the development of novel treatment options, is expected to provide the market with high growth potential.
Crohn's disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals.
On the basis of Therapeutics, Anti-Inflammatory agents led the global market in 2018
Anti-inflammatory agents continued to lead as the largest sub-segment unde the Therapeutics segment of the market in 2018 due to its higher efficacy, compared to immunosuppressant and analgesic, while immune system suppressors is expected to be the fastest-growing segment owing to a reduction in surgeries and hospitalization rates.
A specific category of anti-inflammatory agents includes Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). NSAIDs are among the most commonly used medications for the treatment of Crohn's disease.
North America Holds the Largest Market Share
North America has held the largest market share in the Crohn's disease diagnostic and therapeutic market due to the increasing prevalence of Crohn's disease in the region. Additionally, the Asia-Pacific region is expected to register high growth during the forecast period.
According to the Center for the Disease Control and Prevention (CDC), in the United States, it is currently estimated that about 1.3 million people suffer from inflammatory bowel disorder (IBD). The IBD prevalence includes prevalence for ulcerative colitis (UC) and Crohn's disease. In this region, urbanization is a potential contributing factor for the increasing prevalence of Crohn's disease. The incidence of CD is attributed to the result of "westernization" of lifestyle, such as changes in diet, smoking, differences in exposure to sunlight, pollution, and industrial chemicals.
Overall, the Crohn's disease has been shown to affect North American and Western European countries more heavily than others, with more than 750,000 people living with Crohn's disease in the United States alone.
Crohns disease diagnostic and therapeutic market has growing opportunities both in the developing and nations of the world. However US region controls the majority of market share which can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of Crohn's disease in the region as well as the high annual cost of therapy (ACOT) of Stelara (Johnson & Johnson) and the ACOT of Risankizumab (AbbVie) in the US market.